| P50 | author | Luigi Bubacco | Q38543824 |
| | Marco Bisaglia | Q60973461 |
| | Tiago Fleming Outeiro | Q79139390 |
| P2093 | author name string | Alice Biosa | |
| P2860 | cites work | Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues | Q24306921 |
| | Human DJ-1 and its homologs are novel glyoxalases | Q24316421 |
| | Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism | Q24321359 |
| | Dopamine covalently modifies and functionally inactivates parkin | Q24338423 |
| | AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity | Q24595845 |
| | Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease | Q24632904 |
| | Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models | Q26750648 |
| | Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease | Q26824465 |
| | Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes | Q26865565 |
| | AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function | Q26865723 |
| | Parkinson's disease and immune system: is the culprit LRRKing in the periphery? | Q27687171 |
| | Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 |
| | Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance | Q28077356 |
| | Type 1 diabetes | Q28301396 |
| | Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease | Q28391762 |
| | Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons | Q28553200 |
| | Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins | Q28574891 |
| | Global and societal implications of the diabetes epidemic | Q29614551 |
| | Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies. | Q30385523 |
| | Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct | Q31029246 |
| | Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine | Q33344779 |
| | Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. | Q33355903 |
| | Dopamine-induced conformational changes in alpha-synuclein | Q33500157 |
| | Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. | Q33771253 |
| | Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease | Q34065897 |
| | Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease | Q34181738 |
| | Advanced glycation endproducts: what is their relevance to diabetic complications? | Q34613062 |
| | Diabetes and risk of Parkinson's disease | Q34718429 |
| | Diabetes and the risk of developing Parkinson's disease in Denmark. | Q35043736 |
| | Metformin inhibition of glycation processes | Q35539971 |
| | Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. | Q35898211 |
| | Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53 | Q36002833 |
| | Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). | Q36282886 |
| | Risk of dementia in diabetes mellitus: a systematic review | Q36345254 |
| | Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies | Q36891855 |
| | Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics | Q37156152 |
| | Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons | Q37180671 |
| | Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance | Q37299382 |
| | Structural insights on physiological functions and pathological effects of alpha-synuclein. | Q37307280 |
| | Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis | Q37315448 |
| | Diabetes, oxidative stress, nitric oxide and mitochondria function. | Q37481730 |
| | DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. | Q37584540 |
| | Increased risk of Parkinson disease with diabetes mellitus in a population-based study | Q37613409 |
| | Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome | Q37801856 |
| | Shared dysregulated pathways lead to Parkinson's disease and diabetes | Q38078667 |
| | Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. | Q38086812 |
| | Neuronal vulnerability, pathogenesis, and Parkinson's disease | Q38099288 |
| | Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease? | Q38175706 |
| | Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity | Q38180144 |
| | Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. | Q38195478 |
| | Metformin: from mechanisms of action to therapies | Q38279824 |
| | The role of type 2 diabetes in neurodegeneration | Q38450518 |
| | Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin | Q38675441 |
| | Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. | Q38769539 |
| | Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal | Q38938961 |
| | Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples | Q38972136 |
| | DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease | Q38972171 |
| | Selective neuronal vulnerability in Parkinson disease | Q39095738 |
| | Risk of dementia among persons with diabetes mellitus: a population-based cohort study | Q39441115 |
| | Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence | Q40085533 |
| | Structural and functional changes in human insulin induced by methylglyoxal | Q40275723 |
| | Methylglyoxal toxicity in mammals | Q40678654 |
| | Guanine glycation repair by DJ-1/Park7 and its bacterial homologs | Q41412797 |
| | Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol | Q41786059 |
| | Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation | Q42499319 |
| | Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats | Q42826171 |
| | Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease | Q42987474 |
| | Dopamine quinones interact with alpha-synuclein to form unstructured adducts. | Q43131429 |
| | Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles | Q44550064 |
| | Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. | Q46427562 |
| | Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. | Q46443909 |
| | Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway | Q46537593 |
| | Evidence of oxidative stress in the neocortex in incidental Lewy body disease | Q46686665 |
| | Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease | Q47096119 |
| | Gestational diabetes from A to Z. | Q47155722 |
| | Impaired peripheral glucose homeostasis and Alzheimer's disease | Q47422317 |
| | Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease | Q47954089 |
| | Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets | Q47973063 |
| | Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice | Q48613553 |
| | Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease | Q48888308 |
| | Association of diabetes mellitus and dementia: the Rotterdam Study. | Q50989914 |
| | Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. | Q51063701 |
| | Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. | Q51385393 |
| | Type 2 diabetes and the risk of Parkinson's disease. | Q53016612 |
| | Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. | Q53098272 |
| | Diabetes mellitus and the risk of dementia: The Rotterdam Study. | Q53231897 |
| | Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. | Q53285842 |
| | The Critical Role of Methylglyoxal and Glyoxalase 1 in Diabetic Nephropathy | Q60786520 |
| | Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic Complications | Q60786679 |
| | Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin | Q72352188 |
| | Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation | Q73203933 |
| | Metformin reduces systemic methylglyoxal levels in type 2 diabetes | Q77804967 |
| | Type 2 diabetes | Q89258111 |
| P433 | issue | 11 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 8754-8763 | |
| P577 | publication date | 2018-03-28 | |
| P1433 | published in | Molecular Neurobiology | Q15716645 |
| P1476 | title | Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View | |
| P478 | volume | 55 | |